Arsenal Bio
Business Services · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
329 Oyster Point Blvd, South San Francis...Phone Number
(650) 240-8844Website
www.arsenalbio.comRevenue
$54.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
3
1
1
About Arsenal Bio
Founded in 2019, ArsenalBio is a programmable cell therapy company creating immune cell therapies. They are focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to discover and develop in immune cell therapies. ArsenalBio is headquartered in San Francisco, California.Explore more
Arsenal Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arsenal Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Arsenal Bio had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Arsenal Bio recently announced quarterly report
Product Launch: Get notified when Arsenal Bio launches new products
Check if Arsenal Bio has recently received funding, and reach out quickly before it becomes old news!
Check out if Arsenal Bio is spiking on competitors!
Arsenal Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Arsenal Bio has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Arsenal Bio
Recommended Actions
Find VP level buyers at Arsenal Bio
Find more new buyers
Compare Similar Companies to Arsenal Bio
Compare insights from companies similar to Arsenal Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Arsenal Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Arsenal Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Arsenal Bio.
Arsenal Bio financials insights
Gather financial insights about Arsenal Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$85M
2022
Series B
$220M
2024
Series C
$325M
Arsenal Bio Tech Stack
A closer look at the technologies used by Arsenal Bio
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Event
Events, Engineering, Research & Development, Training, Machine Learning, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Chemical Engineering, Artificial Intelligence, Clinical Operations, Healthcare Technology, HR Operations, Operations
Open Position
Arsenal Bio News & Media
ArsenalBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ArsenalBio CEO Ken Drazan will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, Jan. 13, 2025, at 4pm PST.Nate Hardy to Join Arsenal Biosciences, Inc. as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ArsenalBio--Nate Hardy will join Arsenal Biosciences, Inc. as Chief Financial Officer.Goodwin Advises Arsenal Biosciences on $325 million Series C Funding Round | News & Events
Arsenal Biosciences secures $325M in Series C funding to advance T cell therapies for cancer, enhancing R&D and innovative treatment solutions. Read more about this deal announcement.ArsenalBio: $325 Million (Series C) To Enhance Programmable Cell Therapy Programs
Arsenal Biosciences, a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, announced today the closing of an oversubscribed $325 million Series C financing round.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Arsenal Bio
Sign Up For FreeTo access detailed company insights
Founded in 2019, ArsenalBio is a programmable cell therapy company creating immune cell therapies. They are focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to discover and develop in immune cell therapies. ArsenalBio is headquarter... Read More
